<DOC>
	<DOCNO>NCT01949870</DOCNO>
	<brief_summary>The objective study investigate safety tolerability oral dose selumetinib combination chemotherapy ( cisplatin gemcitabine ) Japanese patient advance biliary tract cancer ( BTC ) . In addition , pharmacokinetic ( PK ) profile selumetinib chemotherapy investigate . Also , Maximum tolerate dose ( MTD ) selumetinib combination chemotherapies Japanese BTC patient identify , possible .</brief_summary>
	<brief_title>Selumetinib ( AZD6244 , ARRY-142886 ) J-BTC Phase 1 Study</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Provision write informed consent 2 . Patients must ≥ 20 year 3 . Histological cytological confirmation locally advance metastatic BTC ( intra extrahepatic , gallbladder ampullary carcinoma ) 4 . Patients eligible treatment standard dose cisplatin/gemcitabine combination regimen 5 . World Health Organisation ( WHO ) performance status ( PS ) 01 6 . Evidence postmenopausal status negative urine/serum pregnancy test nonmenopausal female patient Women consider postmenopausal amenorrheic 1 year without alternative medical cause . The follow agespecific requirement apply : ) Women 50 year old would consider postmenopausal amenorrheic 1 year follow cessation exogenous hormonal treatment Luteinizing hormone ( LH ) Follicle stimulate hormone ( FSH ) level postmenopausal range . ii ) Women 50 year old would consider postmenopausal amenorrheic 1 year follow cessation exogenous hormonal treatment , radiationinduced oophorectomy last menses &gt; 1 year ago , chemotherapyinduced menopause &gt; 1 year interval since last menses . Or surgical sterilisation ( bilateral oophorectomy hysterectomy ) . 7 . Male patient willing use barrier contraception specify period 8 . A lesion accurately assess baseline CT magnetic resonance imaging ( MRI ) suitable repeat assessment accordance RECIST 9 . Patients must life expectancy ≥16 week 10 . Patients remain Hospital Cycle 0 Day 1 least completion Cycle 1 Day 9 11 . Patient willing provide fresh archival tumour sample biomarker blood sample . 1 . Treatment follow : Nitrosourea mitomycin C within 6 week first dose study treatment Any investigational agent study drug previous clinical study within 4 week first dose study treatment Chemotherapy , immunotherapy anticancer agent within 3 week first dose study treatment selumetinib ( therefore , patient already participate study take selumetinib ) MEK ( Mitogenactivated protein kinase kinase Mitogenactivated protein kinase ( MAPK ) / Extracellular signalregulated kinase ( ERK ) kinase ) 1/2 inhibitor past Cisplatin gemcitabine past Major surgery ( exclude placement vascular access ) within 4 week first dose study treatment Radiotherapy wide field radiation within 4 week radiotherapy limited field radiation palliation within 2 week first dose study treatment 2 . With exception alopecia , unresolved toxicity prior therapy ≥Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 3 . Spinal cord compression brain metastasis unless asymptomatic , treat stable require steroid least 4 week prior start study treatment 4 . As judged investigator , evidence severe uncontrolled systemic disease , , active bleeding diatheses active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) severe renal impairment , uncontrolled diabetes renal transplant acute uncontrolled infection current unstable uncompensated respiratory cardiac disease peripheral vascular disease include diabetic vasculopathy Screening chronic condition require 5 . Any following cardiac criterion : Any factor increase risk QTc prolongation risk arrhythmic event ( eg , heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age mean rest correct QT interval ( QTc ) &gt; 470 msec ) Uncontrolled hypertension ( BP≥150/95 mmHg despite medical therapy ) Acute coronary syndrome within 6 month prior start treatment Angina Canadian Cardiovascular Society Grade IIIV ( despite medical therapy ) Symptomatic heart failure ( NYHA [ New York Heart Association ] IIIV ) Prior current cardiomyopathy Baseline leave ventricular ejection fraction ( LVEF ) &lt; 55 % measure echocardiography Multiple Gated Acquisition Scan ( MUGA ) Atrial fibrillation ventricular rate &gt; 100 bpm rest Severe valvular heart disease 6 . Inadequate bone marrow reserve organ function demonstrate follow laboratory value : Absolute neutrophil count &lt; 1.5 x 109/L Platelet count &lt; 100 x 109/L Haemoglobin &lt; 90 g/L Alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) &gt; 2.5 time ULN Total bilirubin &gt; 1.5 time ULN Creatinine clearance &lt; 50 mL/min ( measure calculate Cockcroft Gault equation ) 7 . Any following ophthalmological criterion : Current past history central serous retinopathy retinal vein occlusion Intraocular pressure &gt; 21 mmHg Uncontrolled glaucoma ( irrespective intraocular pressure ) 8 . Inadequate biliary drainage 9 . Symptomatic patient interstitial pneumonitis lung fibrosis confirm plain chest Xray chest CT 10 . Refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate product previous significant bowel resection would preclude adequate absorption selumetinib 11 . History hypersensitivity selumetinib drug similar chemical structure class selumetinib 12 . History hypersensitivity platinum gemcitabine contain drug 13 . Use strong CYP ( Cytochrome P450 ) 1A2 , CYP ( Cytochrome P450 ) 2C19 CYP3A4 inducer and/or inhibitor ( example , limited , fluvoxamine , fluconazole , ticlopidine , ketoconazole , atazanavir , clarithromycin , indinavir , itraconazole , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole , grapefruit seville orange juice fruit , rifampicin , rifabutin , phenytoin , carbamazepine , phenobarbital St. John 's Wort ) 14 . Any contraindication combination chemotherapy per local prescribe information 15 . Judgment investigator patient participate study patient unlikely comply study procedure , restriction requirement 16 . Involvement plan conduct study ( applies AstraZeneca staff staff study site ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>